Ann: Response to ASX Price Query, page-12

Wubung, a deal out of Japan will be a game changer.
Only need a phase II trial to commercialise.
So far the early safety/efficacy profile looks good. In addition, the interest from scientists around the RGS research and technology is strong.
The analyst price target I think is 55c, but of course we have to take this with a grain of salt.
The real deal will be the efficacy of progenza....but so far looking good.
I have been in communication with management previously and feel confident that milestones will be met.
The SP is on a steep parabolic trend. Sharp pullbacks are to be expected, followed by strong growth.